Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 3
1953 1
1956 1
1959 1
1964 1
1980 8
1981 13
1982 28
1983 55
1984 77
1985 96
1986 114
1987 116
1988 80
1989 131
1990 158
1991 165
1992 159
1993 180
1994 176
1995 189
1996 201
1997 170
1998 163
1999 190
2000 165
2001 196
2002 211
2003 185
2004 258
2005 276
2006 214
2007 230
2008 209
2009 214
2010 220
2011 226
2012 210
2013 230
2014 201
2015 186
2016 179
2017 151
2018 181
2019 161
2020 149
2021 33
Text availability
Article attribute
Article type
Publication date

Search Results

6,344 results
Results by year
Filters applied: . Clear all
Page 1
Mitoxantrone, More than Just Another Topoisomerase II Poison.
Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM. Evison BJ, et al. Med Res Rev. 2016 Mar;36(2):248-99. doi: 10.1002/med.21364. Epub 2015 Aug 19. Med Res Rev. 2016. PMID: 26286294 Review.
Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic profile of the anthracyclines and is commonly applied in the treatment of breast and prostate cancers, lymphomas, and leukemias. ...Here, we consider each of these interactions in t
Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic profile of the anthracyclines and is comm
A case of mitoxantrone extravasation.
Chang A. Chang A. J Oncol Pharm Pract. 2020 Jul;26(5):1270-1273. doi: 10.1177/1078155219893736. Epub 2020 Jan 6. J Oncol Pharm Pract. 2020. PMID: 31902285
The literature has been conflicting in classifying mitoxantrone as a vesicant or irritant. CASE REPORT: We report a patient who had an extravasation of mitoxantrone. Mitoxantrone was administered in 50 ml normal saline. After mitoxantrone was completel …
The literature has been conflicting in classifying mitoxantrone as a vesicant or irritant. CASE REPORT: We report a patient who had a …
[Mitoxantrone].
Pericot I, Montalban X. Pericot I, et al. Neurologia. 2003 Jul-Aug;18(6):318-23. Neurologia. 2003. PMID: 12838451 Review. Spanish.
Mitoxantrone is an antineoplastic agent that exerts a potent immunosuppresive effect, including suppression of B cell immunity and reduction of T cell numbers. ...In 2000, the FDA (Food and Drug Administration) approved the use of mitoxantrone for the treatment of a
Mitoxantrone is an antineoplastic agent that exerts a potent immunosuppresive effect, including suppression of B cell immunity and re
Mitoxantrone-Surfactant Interactions: A Physicochemical Overview.
Enache M, Toader AM, Enache MI. Enache M, et al. Molecules. 2016 Oct 13;21(10):1356. doi: 10.3390/molecules21101356. Molecules. 2016. PMID: 27754390 Free PMC article. Review.
Mitoxantrone is a synthetic anticancer drug used clinically in the treatment of different types of cancer. ...The present review describes the physicochemical aspects of the interactions between the anticancer drug mitoxantrone and different surfactants. Mitoxant
Mitoxantrone is a synthetic anticancer drug used clinically in the treatment of different types of cancer. ...The present review desc
Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Martinelli Boneschi F, et al. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD002127. doi: 10.1002/14651858.CD002127.pub2. Cochrane Database Syst Rev. 2005. PMID: 16235298 Updated. Review.
BACKGROUND: Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients. ...
BACKGROUND: Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity …
Mitoxantrone treatment of multiple sclerosis: safety considerations.
Cohen BA, Mikol DD. Cohen BA, et al. Neurology. 2004 Dec 28;63(12 Suppl 6):S28-32. doi: 10.1212/wnl.63.12_suppl_6.s28. Neurology. 2004. PMID: 15623667 Review.
Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events. ...Studies under way address whether concomitant administration of dexrazoxane with mitoxantrone might decrease the risk for cardia …
Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events …
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
Faulds D, Balfour JA, Chrisp P, Langtry HD. Faulds D, et al. Drugs. 1991 Mar;41(3):400-49. doi: 10.2165/00003495-199141030-00007. Drugs. 1991. PMID: 1711446 Review.
Mitoxantrone is also effective as a component of predominantly palliative treatment regimens for hepatic and advanced ovarian carcinoma. ...Thus, mitoxantrone is an effective and better tolerated alternative to the anthracyclines in most haematological malignancies,
Mitoxantrone is also effective as a component of predominantly palliative treatment regimens for hepatic and advanced ovarian carcino
Is there a new place for mitoxantrone in the treatment of multiple sclerosis?
Wawrzyniak S, Rzepiński Ł. Wawrzyniak S, et al. Neurol Neurochir Pol. 2020;54(1):54-61. doi: 10.5603/PJNNS.a2019.0069. Epub 2020 Jan 10. Neurol Neurochir Pol. 2020. PMID: 31922582 Free article.
AIM OF THE STUDY: To compare the clinical and neuroradiological efficacy of mitoxantrone (MTX) in various forms of multiple sclerosis (MS), to ascertain whether there is a new place for the drug in the treatment regimen of the disease, as well as to determine its safety pr …
AIM OF THE STUDY: To compare the clinical and neuroradiological efficacy of mitoxantrone (MTX) in various forms of multiple sclerosis …
[Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis].
Szwed M. Szwed M. Postepy Hig Med Dosw (Online). 2014 Feb 21;68:198-208. doi: 10.5604/17322693.1091102. Postepy Hig Med Dosw (Online). 2014. PMID: 24662788 Free article. Review. Polish.
Mitoxantrone is an antineoplastic agent approved for clinical use in the secondary progressive phase of multiple sclerosis (MS). ...The presented data indicate that, apart from the cytostatic properties, mitoxantrone also exhibits side effects of its clinical applic
Mitoxantrone is an antineoplastic agent approved for clinical use in the secondary progressive phase of multiple sclerosis (MS). ...T
The current role of mitoxantrone in the treatment of multiple sclerosis.
Cocco E, Marrosu MG. Cocco E, et al. Expert Rev Neurother. 2014 Jun;14(6):607-16. doi: 10.1586/14737175.2014.915742. Epub 2014 May 16. Expert Rev Neurother. 2014. PMID: 24834466 Review.
Mitoxantrone is an immunosuppressive drug approved for aggressive relapsing and progressive multiple sclerosis. ...Apart from its role as a second/third-line therapy, some studies suggest its use as an induction therapy. However, mitoxantrone use is limited because
Mitoxantrone is an immunosuppressive drug approved for aggressive relapsing and progressive multiple sclerosis. ...Apart from its rol
6,344 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page